Breast – CLDN18.2 negative invasive breast cancer of no special type (NST).
Breast – CLDN18.2 negative invasive lobular breast cancer.
Colon – CLDN18.2 negative colorectal adenocarcinoma.
Colon – CLDN18.2 negative colorectal adenocarcinoma. (2)
Kidney – CLDN18.2 negative clear cell carcinoma.
Kidney – CLDN18.2 negative oncocytoma.
Kidney – CLDN18.2 negative papillary renal cell carcinoma.
Lung – CLDN18.2 negative malignant mesothelioma (epitheloid).
Lung – CLDN18.2 negative squamous cell carcinoma.
Oral cavity – CLDN18.2 negative squamous cell carcinoma.
Ovary – CLDN18.2 negative clear cell carcinoma.
Ovary – CLDN18.2 negative endometroid carcinoma.
Ovary – CLDN18.2 negative serous high-grade carcinoma.
Pancreas – Ductal adenocarcinoma with distinct membranous CLDN18.2 staining of most tumor cells.
Pancreas – Ductal adenocarcinoma with strong CLDN18.2 staining of tumor cells.
Pancreas – Ductal adenocarcinoma with strong membranous CLDN18.2 staining of all tumor cells.
Pancreas – Ductal adenocarcinoma with strong membranous CLDN18.2 staining of most tumor cells.
Pharynx – CLDN18.2 negative squamous cell carcinoma.
Prostate – CLDN18.2 negative adenocarcinoma (Gleason 3+3=6).
Prostate – CLDN18.2 negative adenocarcinoma (Gleason 4+4=8).
Stomach – Gastric adenocarcinoma (diffuse type) with strong membranous CLDN18.2 staining of most tumor cells.
Stomach – Gastric adenocarcinoma (intestinal type) with strong membranous CLDN18.2 positivity of all tumor cells.
Stomach – Gastric adenocarcinoma (intestinal type) with strong membranous CLDN18.2 positivity of tumor cells.
Testis – CLDN18.2 negative seminoma.
Thyroid – CLDN18.2 negative papillary carcinoma.
Urinary bladder – CLDN18.2 negative muscle-invasive urothelial carcinoma.
Urinary bladder – CLDN18.2 negative non-invasive papillary urothelial carcinoma (pTa).